medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2014, Number 4

<< Back Next >>

Arch Med Fam 2014; 16 (4)

The Contribution of Cannabinoids to Pain Treatment

Godínez CN, Ramírez BA

Language: Spanish
References: 29
Page: 83-88
PDF size: 209.49 Kb.


ABSTRACT

Cannabinoids come from the Cannabis sativa plant known commonly as marijuana. It is native of Asia and it was rapidly naturalized in America. In the beginning of the decade of the 90s, the first specific recipient of membrane for cannabinoids in the nervous system was cloned, and called cannabinoid binding (CB1). Three years later, two new receptors were cloned and characterized pharmacologically. Endocannabinoids are lipidic, bioactive molecules produced in the hippocampus, thalamus, striatum, cerebral cortex, pons, cerebellum and spinal marrow. In the hippocampus, the cannabinoids mediate the inhibition of neurotransmitter gamma amino butyric acid (GABA) in retrograde form. This function has been related to the learning processes. The central effects of the agonistic endocannabinoids of CB1 include decrease of movement, hypothermia and analgesia, among others. The union of the exogenous cannabinoides to its receptors can initiate agonistic functions. These actions have been used for the treatment of different painful sufferings of the human being.


REFERENCES

  1. Villaseñor R, JL, Espinosa G. Catálogo de malezas de México. Universidad Nacional Autónoma de México. Consejo Nacional Consultivo Fitosanitario. México, D.F.: Fondo de Cultura Económica. 1998.

  2. Leslie Iversen, The Science of Marijuana, Oxford University Press, USA; 1st edition (January 15, 2000), pp 1-14.

  3. Leslie Iversen, Cannabis and the brain. Brain (2003) 126 (6): 1252-1270.

  4. Siegel, C., Gordon, P.M., Uliss, D.B.,et al. Synthesis of racemic and optically active Δ9-tetrahydrocannabinol (THC) metabolites. J Org Chem 1991:56(24); 6865-6872.

  5. L. Mestre, et al. Cannabinoides en Esclerosis Múltiple, Rev Neurol 2006; 43 (9): 541-548.

  6. E. Murillo-Rodríguez., Endocanabinoides y Sueño, Rev Neurol 2008; 46 (3): 160-166

  7. J. Manzanares, M. D. Julian and A. Carrascosa. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes.,Current Neuropharmacology, 2006, 4, 239-257

  8. Marco EM, Viveros MP. [Functional role of the endocannabinoid system in emotional homeostasis]. Rev Neurol. 2009 Jan 1-15;48(1):20-6.

  9. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Nsci. Revs. 4 (2003) 873-884.

  10. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci.,2002Nov;(21):9612-7.

  11. J. Manzanares, M. D. Julian and A. Carrascosa. Role of the Cannabinoid System in Pain Control and Therapeutic Implications Current Neuropharmacology, 2006, Vol. 4, No. 3 239-257.

  12. Ibrahim, M.M., Porreca, F., Lai, J., Albrecht, P.J., Rice, F.L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T.W., Mata, H.P., Malan, T.P. Jr. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. USA, 2005;(102): 3093-3098.

  13. Peat S.,Using cannabinoids in pain and palliative care.,Int J Palliat Nurs. 2010 Oct;16(10):481-5.

  14. Ethan B Russo., Cannabinoids in the management of difficult to treat pain.,Ther Clin Risk Manag. 2008 February; 4(1): 245–259.

  15. CADIME., Derivados del cannabis: papel en terapéutica. Rev.Soc.Esp.Dolor.,9:2002;401-404.

  16. Maida V. The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients. J Support Oncol. 2006;6:119-24.

  17. Rice A. Canabinoides en el manejo del dolor neuropático: una revisión corta. Rev. Iberoamericana del Dolor Vol. 4, No. 2, 2009

  18. Nurmikko TJ, Serpell MG, Hoggart B,Toomey PJ, Morlion BJ, Haines Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. DPain.2007 Dec 15;133(1-3):210-20.

  19. Williamsom EM, et al. Cannabinoids in clinical practice. Drugs 2000; 60(6): 1303-10

  20. Wright S., Ware M., Guy G., The use of a cannabis-based medicine ex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jun;45(6):781-4.

  21. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential-.J Ethnopharmacol. 2006 Apr 21;105(1-2):1-25..

  22. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR., Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain., Curr Med Res Opin. 2007 Jan;23(1):17-24.

  23. Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. . J Neurol. 2006 Oct;253(10):1337-41.

  24. Lynch ME, Campbell F., Cannabinoids for Treatment of Chronic Non-Cancer Pain; a Systematic Review of Randomized Trials. Br J Clin Pharmacol. 2011 Mar 23. doi: 10.1111/j.1365-2125.2011.03970.x. [Epub ahead of print]

  25. Bestard JA, Toth CC., An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.Pain Pract. 2011 Jul-Aug;11(4):353-68.

  26. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial. Anesth Analg 2010 Feb 1;110(2):604-10. doi: 10.1213/ANE.0b013e3181c76f70. Epub 2009 Dec 10. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20007734

  27. Skrabek RQ, Galimova L, Ethansand Daryl K. Nabilone for the Treatment of Pain in Fibromyalgia. J Pain. 2007 Oct 30.

  28. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter,Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy,Safety, and Tolerability of THC:CBD Extract andTHC Extract in Patients With Intractable Cancer- Related Pain. J Pain Symptom Manage, 2010 in press.

  29. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M., Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. (Consultado en http://www.cannabis-med.org/spanish/studies.htm#_Toc291681813 el día 23 de octubre 2012). 88




2020     |     www.medigraphic.com